Bicycle Therapeutics is building a platform to develop cyclic peptides that combine the favorable attributes of large and small molecule therapeutics. Bicycle Therapeutics went public in May 2019 (NASDAQ: BCYC).
| Headquarters | Cambridge, UK |
| Website | www.bicycletherapeutics.com |
| Pipeline | Preclinical |
| @Bicycle_tx | |
| Partners | AstraZeneca, Bioverativ, ThromboGenics |